Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study
An erratum to this article was published (Lancet Diabetes Endocrinol, Apr 2026 ↗)
Main finding · MACE, combined GLP-1 RA use and lifestyleResult — go to the resultHazard ratio 0.57 CI 0.46–0.71Authors' conclusion
Adherence to low-risk lifestyle habits combined with GLP-1 receptor agonist use was associated with a greater reduction in MACE risk than either approach alone, underscoring the importance of integrating lifestyle modification with pharmacotherapy in type 2 diabetes management.
Study context
- Population
- Individuals with T2D in the US Veterans Affairs' Million Veteran Program (2011–2023), without previous MI, stroke or advanced CKD
- Participants
- 98,261 individuals632,543 person-years
- Exposure
- GLP-1 RA use and adherence to eight low-risk lifestyle habits vs no GLP-1 RA use and fewer habits
- Outcome
- MACE: non-fatal stroke or MI, or cardiovascular death
Main finding
MACE, combined GLP-1 RA use and lifestyle
Hazard ratio
0.57
CI 0.46–0.71
GLP-1 RA + 6–8 low-risk lifestyle factorsvs No GLP-1 RA + ≤3 low-risk lifestyle factors
HR 0.57 (CI 0.46–0.71)
As reported in the abstract
- Participants developing major adverse cardiovascular events (MACE) during follow-up
- 10 443
Observational data: associations, not effects.
Further findings
| Outcome | Multivariable-adjusted HR | |
|---|---|---|
| MACE, all eight low-risk lifestyle habitsvs one habit or less | 0.40 (95% CI 0.30–0.54) | |
| MACE, GLP-1 RA usersvs non-users | 0.84 (CI 0.76–0.92) | |
| 0.20.5125Multivariable-adjusted HR (log scale) |
Original publication
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. Published 25 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →